Amneal Pharmaceuticals Raises FY2026 Adj EPS Guidance from $0.95-$1.05 to $0.96-$1.06 vs $0.97 Est; Raises FY2026 Sales Guidance from $3.050
Amneal Pharmaceuticals (NASDAQ: AMRX ) raises FY2026 Adj EPS guidance from $0.95-$1.05 to $0.96-$1.06 vs $0.97 analyst estimate. Raises FY2026 sales outlook from $3.050 billion-$3.150 billion to $3.100 billion-$3.200 billion vs $3.103 billion estimate.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.